Tryptase and Protease-Activated Receptor 2 Expression Levels in Irritable Bowel Syndrome.
- Author:
Wen Jing LIANG
1
;
Guo ZHANG
;
He Sheng LUO
;
Lie Xin LIANG
;
Dan HUANG
;
Fa Can ZHANG
Author Information
1. Department of Gastroenterology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China. zhangfacan@126.com
- Publication Type:Original Article
- Keywords:
Irritable bowel syndrome;
Inflammation;
PAR-2;
Tryptases
- MeSH:
Biopsy;
Blotting, Western;
Calcitonin Gene-Related Peptide;
Immunohistochemistry;
Inflammation;
Irritable Bowel Syndrome*;
Mast Cells;
Neuropeptides;
Real-Time Polymerase Chain Reaction;
Receptor, PAR-2*;
Receptors, Proteinase-Activated;
RNA, Messenger;
Substance P;
Tolonium Chloride;
Tryptases*;
Vasoactive Intestinal Peptide
- From:Gut and Liver
2016;10(3):382-390
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Previous studies have revealed that mast cells (MCs) may activate the protease-activated receptors and release of neuropeptides involved in the pathogenesis of irritable bowel syndrome (IBS). The levels of protease-activated receptor 2 (PAR-2) and tryptase can contribute to understanding the pathogenesis of IBS. METHODS: Colonoscopic biopsies were performed of 38 subjects (20 with IBS-diarrhea [IBS-D], eight with IBS-constipation [IBS-C], and 10 healthy volunteers). The mRNA and protein levels of tryptase and PAR-2 were assessed by real-time PCR and Western blot. The levels of vasoactive intestinal peptide (VIP), substance P (SP), and calcitonin gene-related peptide (CGRP) were measured by immunohistochemistry, and MCs were counted by toluidine blue staining. RESULTS: Significant increases in the mRNA expression of tryptase (p<0.05, IBS-D, IBS-C vs control) and PAR-2 (p<0.05, IBS-D, IBS-C vs control) and in the tryptase protein level (p<0.05, IBS-D, IBS-C vs control) were detected in IBS. Elevations of MCs, CGRP, VIP and SP (p<0.05, IBS-D vs control) were observed for IBS-D only. CONCLUSIONS: Tryptase levels may upregulate the function of PAR-2, resulting in the release of neuropeptide and they were correlated with clinical symptoms associated with IBS.
